Buparvaquone CAS 88426-33-9

Introduction：Basic information about Buparvaquone CAS 88426-33-9, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Buparvaquone Basic information

• Product Name: Buparvaquone
• Synonyms: CS-1178;2-((4-(1,1-dimethylethyl)cyclohexyl)methyl)-3-hydroxy-4-naphthalenedione;2-((4-tert-butylcyclohexyl)methyl)-3-hydroxy-1,4-naphthoquinone;butalex;2-[[4-(1,1-dimethylethyl)cyclohexyl]methyl]-3-hydroxy-1,4-naphthalenedione;BW-720C;2-((4-tert-butylcyclohexyl)Methyl)-3-hydroxynaphthalene-1,4-dione;Buparvaquone-d4
• CAS: 88426-33-9
• MF: C21H26O3
• MW: 326.43
• EINECS: 618-162-1
• Product Categories: API;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;john's
• Mol File: 88426-33-9.mol

Buparvaquone Chemical Properties

• Melting point: 178-184°C
• Boiling point: 460.7±45.0 °C(Predicted)
• density: 1.158±0.06 g/cm3(Predicted)
• storage temp.: Sealed in dry,2-8°C
• solubility: DMSO: soluble
• pka: 5.04±0.10(Predicted)
• form: powder
• color: Yellow
• Major Application: forensics and toxicology veterinary
• InChI: InChI=1S/C21H26O3/c1-21(2,3)14-10-8-13(9-11-14)12-17-18(22)15-6-4-5-7-16(15)19(23)20(17)24/h4-7,13-14,24H,8-12H2,1-3H3
• InChIKey: KLLIVCPQDTYMLC-UHFFFAOYSA-N
• SMILES: C1(=O)C2=C(C=CC=C2)C(=O)C(O)=C1CC1CCC(C(C)(C)C)CC1
• CAS DataBase Reference: 88426-33-9(CAS DataBase Reference)

Safety Information

• WGK Germany: 3
• RTECS: QJ5766600
• Storage Class: 11 - Combustible Solids
• Toxicity: LD50 orally in rats: >2 g/kg (Hudson)

Buparvaquone Usage And Synthesis

Chemical Properties

Yellow Crystalline Solid

Uses

Analog of antimalarial hydroxynaphthoquinones; tert-butyl derivative of Parvaquone. Antiprotozoal (Theileria)

Biological Activity

Buparvaquone is a second-generation hydroxynaphthoquinone antiprotozoal drug related to parvaquone and atovaquone. Buparvaquone is indicated for the therapy and prophylaxis of all forms of Theileriosis and found to have an anti-Leishmanial activity.

in vivo

Treatment of N.?caninum infected mice with buparvaquone (100?mg/kg) either by intraperitoneal injection or gavage prevents neosporosis symptoms in 4 out of 6 mice in the intraperitoneally treated group, and in 6 out of 7 mice in the group receiving oral treatment^[1]. Both a hydrous gel and water-in-oil emulsion of buparvaquone significantly reduce cutaneous parasite burden and lesion size, compared with the untreated control^[3].